依洛尤单抗治疗超高危冠心病的有效性和安全性  

Efficacy and safety of evolocumab in the treatment of ultra high-risk coronary heart disease

作　　者：史周乾 陈雪斌[1] 吕建华[2] 李庆勇[1] 汪凤兰[1] Shi Zhouqian;Chen Xuebin;Lyu Jianhua;Li Qingyong;Wang Fenglan(Department of Cardiology,Puyang People’s Hospital,Puyang 457000,China;Department of Pharmacy,Puyang People’s Hospital,Puyang 457000,China)

机构地区：[1]濮阳市人民医院心内科,濮阳457000 [2]濮阳市人民医院药学部,濮阳457000

出　　处：《中国实用医刊》2023年第16期97-100,共4页Chinese Journal of Practical Medicine

摘　　要：目的探讨依洛尤单抗治疗超高危冠心病的有效性和安全性。方法抽取2021年1月至2022年12月濮阳市人民医院收治的80例超高危冠心病患者为研究对象,采用随机数字表法分为对照组与观察组,每组40例。对照组采用常规治疗,观察组在对照组治疗基础上联合依洛尤单抗治疗。3个疗程后评估患者的临床疗效、心功能指标、脂代谢水平、心肌损伤标志物水平及治疗安全性。结果观察组总有效率(92.50%,37/40)高于对照组(75.00%,37/40),P<0.05。治疗后,观察组左室射血分数、心输出量高于对照组,左心室舒张末期内径、左心室舒张末期容积低于对照组(P<0.05)。治疗后,观察组脂代谢各项指标水平均优于对照组(P均<0.05)。治疗后,观察组肌酸激酶、肌酸激酶同工酶、乳酸脱氢酶水平低于对照组(P<0.05)。治疗期间,两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论依洛尤单抗治疗超高危冠心病患者疗效显著,可改善患者的心功能,调整脂代谢水平,降低心肌酶谱指标水平,治疗安全性良好。Objective To investigate the efficacy and safety of evolocumab in the treatment of ultra high-risk coronary heart disease.Methods Eighty patients with ultra high-risk coronary heart disease admitted to Puyang People’s Hospital from January 2021 to December 2022 were selected as research objects,and they were divided into control group and observation group by random number table method,with 40 cases in each group.The control group was treated by routine therapy,while the observation group was treated with evolocumab based on the treatment of the control group.The clinical efficacy,cardiac function indicators,levels of lipid metabolism indicators,levels of myocardial injury markers,and treatment safety were evaluated after 3 courses of treatment.Results The total effective rate of the observation group(92.50%,37/40)was higher than that of the control group(75.00%,37/40),P<0.05.After treatment,the observation group had higher left ventricular ejection fraction,higher cardiac output,lower left ventricular end-diastolic diameter and lower left ventricular end-diastolic volume,compared with the control group(P<0.05).After treatment,the levels of lipid metabolism indicators in the observation group were superior to those in the control group(all P<0.05).After treatment,the levels of creatine kinase,creatine kinase isoenzyme and lactate dehydrogenase in the observation group were lower than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment period(P>0.05).Conclusions Evolocumab has a significant therapeutic effect on ultra high-risk coronary heart disease,which can improve heart function,regulate lipid metabolism level,and lower levels of myocardial enzyme indexes,with good treatment safety.

关 键 词：冠心病 依洛尤单抗 临床疗效 安全性 心功能 心肌酶谱 

分 类 号：R541.4[医药卫生—心血管疾病]